Top-News
Quelle: - pixabay.com:
BioMarin to Host Investor Day Today at 10:30 a.m. Eastern Time
NEW YORK, Sept. 4, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will host its Investor Day today in New York. The event begins at 10:30 a.m. Eastern Time and can be accessed virtually here.
Led by President and Chief Executive Officer Alexander Hardy, the event will feature presentations from BioMarin's leadership team as they introduce strategic priorities that underscore BioMarin's commitment to deliver significant value creation. A question-and-answer session will follow prepared remarks.
BioMarin's Investor Day Agenda:
- BioMarin's New Corporate Strategy to Deliver Significant and Sustained Value Creation to Stakeholders
Alexander Hardy, President and Chief Executive Officer
- Value Commitment: Financial Strategy to Deliver High Growth and Superior Returns
Brian Mueller, Executive Vice President, Chief Financial Officer
- Innovation Strategy to Deliver Sustainable Pipeline of High Impact Medicines
Hank Fuchs, M.D., President, Worldwide R&D
- Commercial Growth Strategy:
- o Optimizing BioMarin's Growing and Durable Enzyme Therapies Business Unit
- o Building Leadership in Achondroplasia to Set the Stage for Multiple New Indications
Cristin Hubbard, Executive Vice President, Chief Commercial Officer
A link to the live webcast, replay and presentation slides will be available on BioMarin's Investor Relations website for at least 12 months at investors.biomarin.com.
About BioMarin
Founded in 1997, BioMarin is a global biotechnology Company dedicated to transforming lives through genetic discovery. The Company develops and commercializes targeted therapies that address the root cause of genetic conditions. BioMarin's unparalleled research and development capabilities have resulted in eight transformational commercial therapies for patients with rare genetic disorders. The Company's distinctive approach to drug discovery has produced a diverse pipeline of commercial, clinical, and pre-clinical candidates that address a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a substantial benefit over existing treatment options. For additional information, please visit www.biomarin.com.
| Contacts: | |
| | |
| Investors | Media |
| Traci McCarty | Marni Kottle |
| BioMarin Pharmaceutical Inc. | BioMarin Pharmaceutical Inc. |
| (415) 455-7558 | (415) 218-7111 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-host-investor-day-today-at-1030-am-eastern-time-302237727.html
SOURCE BioMarin Pharmaceutical Inc.
Für dich aus unserer Redaktion zusammengestellt
Community-Beiträge zu BioMarin Pharmaceutical Inc
30.06.2023 - 15:23 Uhr
Vassago BMRN 90$
Hämophilie-A-Gentherapie von BioMarin erhält US-Zulassung
das FDA-Label beschreibt einen kleineren Nutzen (annualisierte Blutungsrate), als das Unternehmen zuvor angegeben hatte
https://pharmaphorum.com/news/biomarins-haemophilia-gene-therapy-gets-us-approval
18.03.2023 - 16:28 Uhr
Vassago BMRN 92$
Zahlen für 2022
Umsatz 2,096 Mrd. $ (+14%)
FY23 Umsatzausblick +15%Gewinn 142 Mio. $ / EPS 0,75$ (FY23 Ausblick +30%)Cash 1,63 Mrd. $
MK 17,4 Mrd. $
https://investors.biomarin.com/2023-02-27-BioMarin-Announces-Record-Fourth-Quarter-and-Full-Year-2022-Total-Revenues-Driven-by-Strong-Global-Demand-for-VOXZOGO-R-and-Steady-Growth-of-...
Jetzt anmelden und diskutieren
Registrieren
Login
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.